Amgen Inc. $AMGN Stock Bought by Sumitomo Mitsui DS Asset Management Company Ltd

Key Points

• Sumitomo Mitsui DS Asset Management increased its Amgen stake by 0.9% in the third quarter, bringing its holdings to 324,455 shares valued at approximately $136.8 million. Institutional investors collectively own 76.5% of AMGN.
• Amgen reported quarterly earnings and revenue above analyst expectations, with EPS of $6.29 and revenue of $10.05 billion, while maintaining a quarterly dividend of $2.52 per share.
• Analyst sentiment remains mixed, with the stock carrying an overall “Hold” rating and an average price target of $387.93; meanwhile, insiders sold 6,222 shares worth roughly $2.54 million over the past three months.

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 324,455 shares of the medical research company's stock after buying an additional 2,758 shares during the quarter. Amgen accounts for 0.9% of Sumitomo Mitsui DS Asset Management Company Ltd's investment portfolio, making the stock its 20th largest holding. Sumitomo Mitsui DS Asset Management Company Ltd owned 0.06% of Amgen worth $136,761,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Wellington Altus USA Inc. lifted its stake in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock valued at $28,000 after acquiring an additional 34 shares in the last quarter. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after acquiring an additional 63 shares during the last quarter. Nvwm LLC grew its stake in shares of Amgen by 412.5% in the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company's stock worth $35,000 after acquiring an additional 66 shares in the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Amgen in the 2nd quarter worth $36,000. Finally, Evergreen Advisors LLC bought a new stake in shares of Amgen in the 1st quarter worth $37,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed IMDELLTRA, Amgen’s treatment for extensive-stage small-cell lung cancer. If final requirements are met, the recommendation could improve patient access and create an additional commercial opportunity for the drug. PBAC conditionally backs IMDELLTRA
• Positive Sentiment: Exchange-traded funds reportedly purchased approximately $19.4 million of Amgen shares on October 15, indicating institutional demand that may provide some technical support for the stock. ETFs bought Amgen shares
• Positive Sentiment: Recent analyst coverage includes a reported Wall Street Zen rating upgrade, while broader commentary highlights Amgen’s established portfolio, dividend, and potential next growth wave. The company’s latest reported quarter also exceeded earnings and revenue expectations, supporting the underlying financial case. Amgen rating upgraded
• Neutral Sentiment: Amgen has attracted increased attention on Zacks and other investment platforms. The coverage is largely a recap of factors investors should monitor—including pipeline execution, valuation, competition, and future earnings—rather than a new fundamental announcement. Amgen attracting investor attention
• Negative Sentiment: Investor commentary emphasizes that Amgen has reliable cash flow and a dividend but now needs stronger growth. That concern may be weighing on sentiment, particularly with the stock near its 52-week high and investors expecting newer products and pipeline programs to offset slower growth from mature medicines. Amgen needs growth

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 over the last three months. Insiders own 0.85% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on AMGN shares. Bank of America increased their target price on shares of Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a report on Wednesday, August 5th. Jefferies Financial Group restated a "hold" rating and set a $410.00 price target on shares of Amgen in a report on Wednesday, September 23rd. Oppenheimer restated an "outperform" rating on shares of Amgen in a report on Wednesday, September 23rd. Morgan Stanley reduced their price objective on shares of Amgen from $362.00 to $359.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 7th. Finally, Mizuho increased their price objective on shares of Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $387.93.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $424.94 on Tuesday. The company's 50-day moving average is $415.69 and its 200 day moving average is $375.45. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market capitalization of $229.74 billion, a P/E ratio of 26.41, a price-to-earnings-growth ratio of 3.17 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the prior year, the business earned $6.02 earnings per share. The firm's revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.